This is a multicenter, prospective cohort study aimed at facilitating identification of individuals with ATTR-CA. We will identify subjects with previous LSS surgery who have evidence of TTR amyloid deposits in their spinal specimens. Those with localized TTR in their spinal tissue will be invited to an on-site visit and be evaluated for the presence of clinical manifestations of ATTR cardiac amyloidosis (ATTR-CA).
Search Tufts Medicine
This research study is a 3-week clinical trial of dronabinol, a synthetic form of tetrahydrocannabinol (THC). This study is being done to determine if dronabinol is a safe and effective treatment for agitation symptoms related to Alzheimer’s disease. This study will compare dronabinol to a placebo.
Our main goal is to use a special type of microscopic imaging to help detect cervical pre-cancers without the need for labels or dyes. We've been working closely with doctors at Tufts Medical Center for more than ten years and have studied images from over seventy cervical tissue samples taken from humans. We shine a laser on the tissues with two different types of light, and this caused certain molecules in the cells to give off light, which we collected and analyzed. By scanning the tissues in this way, we could make 3D images and measure how the cell structures changed with depth.
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, symptomatic AS. The primary objective is to demonstrate the safety and effectiveness of the Medtronic TAVR system (on the background of GDMT) is superior to GDMT alone.
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, efficacy and safety study of subjects with Progressive Pulmonary Fibrosis (PPF) treated with inhaled treprostinil over a 52-week period
This is a randomized, open-label study of HLX10 plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: Arm A (HLX10): HLX10 + chemotherapy (carboplatin-etoposide) Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body.
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels.
The study will consist of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.